Big Buttons

• Let’s talk about that Lilly announcement

  There’s been plenty of coverage of Eli Lilly’s announcement this week that it will sell vials of Zepbound directly to consumers at a discount. But the company seems to have left out a few important caveats. read more →

• Our response to the op-ed in The Hill

  The Hill published an editorial by Dr. Kenneth McCall titled “Fake, unsafe weight-loss drugs are a worsening public health dilemma” in which he makes unfounded claims about pharmacy compounding. Here’s the response from our CEO. read more →

• The shortage ends … then what? (Find out at CCH) 

  We’ve added a new session to the Compounders on Capitol Hill lineup. Don’t miss the discussion of what’s on many a compounder’s (and regulators’ … and reporters’...) mind. read more →

• A new bronze corporate patron

  A big welcome to Ro, APC’s newest tier-level corporate patron! read more →

• Education (and CE) from USP

  For the fourth year in a row, USP will be holding a hybrid live/virtual workshop dedicated to improving the quality of compounding. read more →

• Compounding post-Chevron

  At least three issues affecting pharmacy compounding might be affected by the overturning of the decades-old “Chevron doctrine.” read more →

• 503B sourcing: our state-by-state analysis

  Do you work for one of APC’s PFMs? If you’re with a Pharmacy/Facility Member, you’ve got access to a new resource. read more →

• What we’ll be talking about at CCH

  When we get together on Capitol Hill to meet with legislators and their staffs, as much as we’d like to talk about a half-dozen issues (easily!), we’re going to be focusing on the three most important.  read more →

More News

The good news:
Just two months into the launch of phase two of APC’s Campaign to Save cBHT, the metrics are absolutely stellar:

• 1,500 new messages to members of Congress
• 96 new patient testimonials
• 35,000 page views at compounding.com
• 15 million impressions – that’s eyeballs on our new campaign ads!

The very bad news:
The above efforts cost money and the campaign is running out of it. We have funding through July 31, and that’s all. No exaggeration here: Without an immediate infusion of funding, we will be forced to pull all search and digital ads through the end of the year, and our ability to afford to maintain compounding.com as the campaign landing page will be unsure.

Click here to hear what your colleagues are saying about the threat.

Consider this a plea. We have the metrics to prove that the campaign is engaging patients and prescribers and policy-makers in the effort to protect compounded hormone therapy from undue restriction by FDA.

What we don’t have is the money to continue the fight.

We need to raise at least $200,000 in the next three weeks in order to continue. If your business benefits from compounded hormone therapy, NOW is the time to give. We can’t go on without you.